Mesenchymal stem cells therapeutic potential alleviate lipopolysaccharide-induced acute lung injury in rat model.

Inhalation of bacterial endotoxin induces an acute inflammation in the lower respiratory tract. The current study examined the therapeutic effects of bone marrow mesenchymal stem cells (BM-MSCs) in lipopolysaccharide (LPS)-induced pulmonary congestion in rats as compared with dexamethasone (Dexa) and sodium bicarbonate (NaHCO ). LPS (20 µL of LPS of Escherichia coli in each nostril for two consecutive days) induced lung injury as marked by an elevation of number of inflammatory cells especially neutrophils, increased total protein levels, elevation of lipid peroxidation, and reduction of reduced glutathione in bronchoalveolar lavage along with the reduction of reduced glutathione. These deleterious effects were hampered after treatment with BM-MSCs (1 × 10  cells/rat) once before acute lung injury (ALI) induction with LPS to an even better extent than Dexa (2 mg/kg once, ip) and NaHCO (10-15 mL/day for two consecutive days). In summary, BM-MSCs have the ability to suppress the endotoxin-induced systemic inflammatory response and could prove to be a novel approach to therapy for ALI in rats.